Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Valerina Changarathil

Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

November 15, 2024
Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.
Read Transcript

Ellerston Capital portfolio manager Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Speaking at the Sohn Australia conference in Adelaide on Friday, Mr Kourtis lifted the entertainment quotient with his inimitable presentation style, all while donning a doctor’s white coat.

The well known avowed contrarian investor, with over 40 years experience, last year picked then unloved stock ResMed, which has gained more than 60 per cent in the last 12 months to currently trade close to $36 on the ASX.

Ellerston Capital, headquartered in Sydney, has over $5bn invested in traditional and alternative assets and Mr Kourtis told the conference his fund’s single biggest position is in Perpetual.

“The patient I’m diagnosing today, is suffering from a severe case of shareholder wealth destruction – it’s Perpetual!” he said at the conference, which raises money for medical research.

“Perpetual is at a 20-year low. It wasn’t that long ago the stock was at $80. The problem has been very poor leadership at the very top, poor capital allocation and woeful execution.”

Recent deals, including the $2bn acquisition of rival fund manager Pendal that was completed in early 2023 left the asset manager saddled with debt.

Perpetual in May inked a deal with private equity giant KKR to sell its wealth and corporate trust divisions, along with the 138-year-old Perpetual name, in a deal still to be voted on by shareholders.

Last month, Perpetual received a first strike against its executive pay, with Mr Kourtis saying “we’re not going to reward for poor execution”.

Perpetual is now working through a $2.2bn deal with global equity giant KKR. Perpetual will sell its name, along with its prized wealth management business to KKR and focus on a streamlined asset management function.

Perpetual’s corporate trust business will also be part of the KKR deal, with proceeds being used to pay off debt for the group which was worth $771m as of the end of April and the rest returned to shareholders.

“There’ll be some debt repaid, separation costs, net adjustments – but at the end of the day, shareholders are going to receive about a billion dollars,” Mr Kourtis said.

“What does that leave us with? A high quality operating platform, $222bn assets under management, we all know the brands. Importantly 70 per cent of their funds under management, is about to overperform the benchmark.”

He said Perpetual’s problem was its “empire building” likening its Pitt Street office in Sydney to “the Taj Mahal, fit for a Saudi prince”.

“That’s going to get sorted out.”

“It will be the cheapest listed asset manager of scale in the universe … The implied enterprise value of Residual Co is going to be under 4x EBITDA. That is cheap!”

He is backing new chief executive Bernard Reilly, who is prioritising fixing its operating model and cost base.

“Bernie understands cost-cutting and if they can’t take 10 per cent out of that cost base … I’ll give up my doctorship”, he said

Mr Kourtis said “lots could go wrong” with his bet, including issues with the approvals or the tax relief ruling despite his “serious regression analysis”.

But investors would still be “back to the future” with a “pretty decent fund manager”.

“You are basically getting a fund manager for nothing.”

75 per cent of their strategies have outperformed over a three-year period and is good track record, he said.

“The problem hasn’t been performance. It has been with the board, the ex-CEO (Rob Adams) and the execution strategy”.

He said his tip came with an important disclaimer – “we accept no liability for nothing”.

“It really is a gift”, he said, revealing he is “long 10 per cent higher”.

“I am giving you all a fighting headstart”.

Perpetual shares are up nearly 3 per cent to $20.98 in current trading.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Ellerston Capital portfolio manager Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Speaking at the Sohn Australia conference in Adelaide on Friday, Mr Kourtis lifted the entertainment quotient with his inimitable presentation style, all while donning a doctor’s white coat.

The well known avowed contrarian investor, with over 40 years experience, last year picked then unloved stock ResMed, which has gained more than 60 per cent in the last 12 months to currently trade close to $36 on the ASX.

Ellerston Capital, headquartered in Sydney, has over $5bn invested in traditional and alternative assets and Mr Kourtis told the conference his fund’s single biggest position is in Perpetual.

“The patient I’m diagnosing today, is suffering from a severe case of shareholder wealth destruction – it’s Perpetual!” he said at the conference, which raises money for medical research.

“Perpetual is at a 20-year low. It wasn’t that long ago the stock was at $80. The problem has been very poor leadership at the very top, poor capital allocation and woeful execution.”

Recent deals, including the $2bn acquisition of rival fund manager Pendal that was completed in early 2023 left the asset manager saddled with debt.

Perpetual in May inked a deal with private equity giant KKR to sell its wealth and corporate trust divisions, along with the 138-year-old Perpetual name, in a deal still to be voted on by shareholders.

Last month, Perpetual received a first strike against its executive pay, with Mr Kourtis saying “we’re not going to reward for poor execution”.

Perpetual is now working through a $2.2bn deal with global equity giant KKR. Perpetual will sell its name, along with its prized wealth management business to KKR and focus on a streamlined asset management function.

Perpetual’s corporate trust business will also be part of the KKR deal, with proceeds being used to pay off debt for the group which was worth $771m as of the end of April and the rest returned to shareholders.

“There’ll be some debt repaid, separation costs, net adjustments – but at the end of the day, shareholders are going to receive about a billion dollars,” Mr Kourtis said.

“What does that leave us with? A high quality operating platform, $222bn assets under management, we all know the brands. Importantly 70 per cent of their funds under management, is about to overperform the benchmark.”

He said Perpetual’s problem was its “empire building” likening its Pitt Street office in Sydney to “the Taj Mahal, fit for a Saudi prince”.

“That’s going to get sorted out.”

“It will be the cheapest listed asset manager of scale in the universe … The implied enterprise value of Residual Co is going to be under 4x EBITDA. That is cheap!”

He is backing new chief executive Bernard Reilly, who is prioritising fixing its operating model and cost base.

“Bernie understands cost-cutting and if they can’t take 10 per cent out of that cost base … I’ll give up my doctorship”, he said

Mr Kourtis said “lots could go wrong” with his bet, including issues with the approvals or the tax relief ruling despite his “serious regression analysis”.

But investors would still be “back to the future” with a “pretty decent fund manager”.

“You are basically getting a fund manager for nothing.”

75 per cent of their strategies have outperformed over a three-year period and is good track record, he said.

“The problem hasn’t been performance. It has been with the board, the ex-CEO (Rob Adams) and the execution strategy”.

He said his tip came with an important disclaimer – “we accept no liability for nothing”.

“It really is a gift”, he said, revealing he is “long 10 per cent higher”.

“I am giving you all a fighting headstart”.

Perpetual shares are up nearly 3 per cent to $20.98 in current trading.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Nov 15, 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
January 18, 2023

Claremont Global: Investment Case for Nike

Equity Mates are joined by Head of Claremont Global Bob Desmond to discuss his 2022 conference pick, Nike. In the episode Bob unpacks the key metrics, the bull case and the bear case for Nike.

Read More
January 5, 2023

Why Transurban will always be one step ahead of inflation

Loathed by motorists, but loved by investors. Transurban came under focus when Catherine Allfrey nominated the roads operator as her top pick at the recent Sohn Hearts & Minds Conference.

Read More
November 18, 2022

Behind the mega-themes shaping top stockpickers

These are the mega-themes the smartest minds in the market are now firmly getting behind which they believe can help them deliver outsized profits.

Read More
November 18, 2022

Don’t rush to invest yet, fund manager tells Sohn event

Fund manager turned anti-corruption campaigner Bill Browder is advising investors to hang on to their cash until central banks stop raising interest rates and the cost of living starts to come down.

Read More
November 18, 2022

Fund managers go global for top Sohn conference stock picks over Aussie companies

SH&M had before Friday’s event made more than $40m in collective donations to medical research.

Read More
November 18, 2022

Fundies and billionaires party in Hobart

Two hundred of Australia’s best and brightest money managers, bankers and entrepreneurs toasted the seventh Sohn Hearts and Minds conference at David Walsh’s MONA.

Read More
November 18, 2022

Hearts racing: Rich listers rendezvous for speed-dating style stock picking

A room filled with 700 of the country’s financial luminaries and billionaires is a difficult place to pitch an investment idea but it’s a great place to raise money for charity.

Read More
November 18, 2022

How MONA’s David Walsh shocked our top stock pickers

Professional gambler and arts impresario David Walsh had a brutal message for successful top money managers – you may just be lucky.

Read More
November 18, 2022

Why Sohn’s top stock pickers want investors to play it safe

Top global money managers are telling investors to steer clear of companies that don’t make money and invest instead in unloved but profitable businesses.

Read More
November 17, 2022

Five years on, what are the best Sohn stock picks to date?

Some of the top fund managers in the country will on Friday pitch their best investment ideas to the Sohn Hearts & Minds conference.

Read More
November 17, 2022

Low debt counts for everything, says Perpetual’s Aboud

Perpetual’s top stock picker Anthony Aboud makes his money running against the crowd and this is why property trusts like Charter Hall are sitting right the top his list right now.

Read More
November 17, 2022

Perpetual’s Aboud says bet on balance sheets in turbulent markets

Perpetual’s Anthony Aboud says companies with strong balance sheets will finally be rewarded for their discipline in a time of global market upheaval.

Read More
November 16, 2022

How Gerry Cardinale of RedBird Capital tries to double his money investing in sport

The owner of AC Milan and a host of other soccer, cricket, baseball and ice hockey assets is trying to double his money in the ‘resilient’ asset class.

Read More
November 14, 2022

Think outside the box for green investment opportunities

James Miller, Portfolio Manager at Firetrail Investments, believes investors need to stop seeing the global decarbonisation push as a risk – and start seeing it as an opportunity.

Read More
November 14, 2022

Tim Carleton is backing the Aussie dream all the way

Carleton’s conviction will be on full display on Friday when he makes his third appearance at the Sohn Hearts & Minds Conference, where stock-pickers share their best ideas in the name of medical research.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.